Literatur
- 01
Keith D S, Nichols G A, Gullion C M, et al .
Longitudinal follow-up and outcomes among a population with chronic kidney disease
in a large managed care organization.
Arch Intern Med.
2004;
164
659-663
- 02
Ronco C , Haapio M , House A A, et al .
Cardiorenal syndrome.
J Am Coll Cardiol.
2008;
52
1527-1539
- 03
Wanner C , Krane V , März W , et al .
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
N Engl J Med.
2005;
353
238-248
- 04
Coresh J , Selvon E , Stevens L A, et al .
Prevalence of chronic kidney disease in the United States.
JAMA.
2007;
298
2038-2047
- 05
Go A S, Chertow G M, Fan D , et al .
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med.
2004;
351
1296-1305
- 06
Sarnak M J, Levey A S, Schoolwerth A C, et al .
Kidney disease as a risk factor for development of cardiovascular disease: a statement
from the American Heart Association Councils on Kidney in Cardiovascular Disease,
High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Circulation.
2003;
108
2154-2169
- 07
Blacher J , Guerin A P, Pannier B , et al .
Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage
renal disease.
Hypertension.
2001;
38
938-942
- 08
Rodriguez-Garcia M , Gomez-Alonso C , Naves-Diaz M , et al .
Vascular calcifications, vertebral fractures and mortality in haemodialysis patients.
Nephrol Dial Transplant.
2009;
24
239-246
- 09
Block G A, Raggi P , Bellasi A , et al .
Mortality effect of coronary calcification and phosphate binder choice in incident
hemodialysis patients.
Kidney Int.
2007;
71
438-441
- 10
Schlieper G , Krüger T , Djuric Z , et al .
Vascular access calcification predicts mortality in hemodialysis patients.
Kidney Int.
2008;
74
1582-1587
- 11
Teng M , Wolf M , Ofsthun M N, et al .
Activated injectable vitamin D and hemodialysis survival: a historical cohort study.
J Am Soc Nephrol.
2005;
16
1115-1125
- 12
Teng M , Wolf M , Lowrie E , et al .
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
N Eng J Med.
2003;
349
446-456
- 13
Lee G H, Benner D , Regidor D L, et al .
Impact of kidney bone disease and its management on survival of patients on dialysis.
J Ren Nutr.
2007;
17
38-44
- 14
Kalantar-Zadeh K , Kuwae N , Regidor D L, et al .
Survival predictability of time-varying indicators of bone disease in maintenance
hemodialysis patients.
Kidney Int.
2006;
70
771-780
- 15
Sprague S M, Llach F , Amdahl M , et al .
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
Kidney Int.
2003;
63
1483-1490
- 16
Dobnig H , Pilz S , Schamagl H , et al .
Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin
d levels with all-cause and cardiovascular mortality.
Arch Intern Med.
2008;
168
1340-1349
- 17
Mizobuchi M , Finch J L, Martin D R, Slatopolsky E .
Differential effects of vitamin D receptor activators on vascular calcification in
uremic rats.
Kidney Int.
2007;
72
709-715
- 18
Bodyak N , Ayus J C, Achinger S , et al .
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium
in Dahl salt-sensitive animals.
Proc NatlAcadSciUSA.
2007;
104
16810-16815
- 19
Deb D K, Sun T , Wong K E, et al .
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development
of kidney disease in a model of type 2 diabetes.
Kidney Int.
2010;
77
1000-1009
- 20
Kong J , Kim G H, Weis M , et al .
Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive
rats.
Am J Pathol.
2010;
177
622-631
- 21
Llach F , Yudd M .
Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Am J Kidney Dis.
2001;
38 (5 Suppl. 5)
S45-S50
- 22
Schumock G T, Walton S M, Lee T A, et al .
Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism
in patients receiving hemodialysis.
Nephron Clin Pract.
2010;
117
c151-c159
[Epub ahead of print]
01 Selective VITamin D receptor activator for Albuminuria Lowering
02 Paricalcitol benefits in Renal disease Induced cardiac MOrbidity
